RT Journal Article
SR Electronic
T1 PREDICTING THE EVOLUTION OF COVID-19 IN PORTUGAL USING AN ADAPTED SIR MODEL PREVIOUSLY USED IN SOUTH KOREA FOR THE MERS OUTBREAK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.18.20038612
DO 10.1101/2020.03.18.20038612
A1 Teles, Pedro
YR 2020
UL http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038612.abstract
AB Since original reports in Wuhan, China, the new coronavírus covid-19 has spread very quickly worldwide, leading the World Health Organization (WHO) to declare a state of pandemic. Moreover, as of the 13th of March 2020, the WHO has announced that the European continent is now the main centre of the pandemic. Many European governments have already implemented harsh measures to attempt to contain the spread of the virus. In Portugal, there are, as of the 18th of March 2020, 642 confirmed cases. In this study, I applied an adapted SIR model previously used in South Korea to model the MERS outbrake, which is also caused by a coronavirus, to estimate the evolution of the curve of active cases in the case of the Portuguese situation. As some of the parameters were unknown, and the data for Portugal is still scarce, given that the outbreak started later (first case on the 2nd of March) I used Italian data (first reported case in Italy on the 31st of January) to predict them. I then construct two or three different scenarios for the evolution of covid-19 in Portugal, considering both the effectiveness of the mitigation measurements implemented by the government, and the self-protective measures taken by the population, as explained in the South Korean model. In the out of control scenario, the number of active cases could reach as much as ∼40,000 people by the beginning of April. If measures are appropriately taken this number can be reduced to about 700 cases. In case that some measures are taken, but their implementation isn’t done appropriately, the active cases could reach circa 7,000 people. The actual figures probably lie between the interval (∼700-7,000) and the peak will be reached between 9th and the 20nd of April 2020.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of it available publically.